Skip to main content
Clinical Trials/EUCTR2020-001033-12-DK
EUCTR2020-001033-12-DK
Active, not recruiting
Phase 1

PROPHYLACTIC ANTIBIOTIC TREATMENTIN END-STAGE KIDNEY DISEASE AND CENTRAL VENOUS CATHETER ASHEMODIALYSIS VASCULAR ACCESS

iels Eske Bruun0 sites800 target enrollmentApril 17, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Severe infection in patients end stage kidney disease and in hemodialysis with CVC as vascular asscess.
Sponsor
iels Eske Bruun
Enrollment
800
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 17, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
iels Eske Bruun

Eligibility Criteria

Inclusion Criteria

  • End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV\-fistula or AV\-graft))
  • \> 18 years
  • Ability to understand the study background, risk and benefit of treatment and to give written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 300
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 500

Exclusion Criteria

  • Unable to give informed consent
  • Known intolerance to beta\-lactam antibiotics and clindamycin
  • Active infection treated with antibiotics.
  • Pregnancy. In women of childbearing age, an approved birth control must be ensured.
  • Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible

Outcomes

Primary Outcomes

Not specified

Similar Trials